Moriki T, Takahashi T, Kataoka H, Hiroi M, Yamane T, Hara H
Department of Clinical Laboratory Medicine, Kochi Medical School, Japan.
Pathol Int. 1996 Dec;46(12):953-61. doi: 10.1111/j.1440-1827.1996.tb03574.x.
The proliferative activity of 30 cases of non-treated invasive ductal breast carcinoma was evaluated by bromodeoxyuridine (BrdU), proliferation marker (MIB-1) and proliferating cell nuclear antigen (PCNA), and the relation between these proliferation markers and histological subtype and histological grade were investigated. In addition, the association of these proliferation markers with overexpression of p53 protein, c-erbB-2 oncoprotein, estrogen receptor (ER) status and clinicopathologic findings were also examined. The BrdU labeling index (LI), MIB-1 score and PCNA labeling rate (LR) correlated with the histological grade. However, there was no statistical difference in proliferative activity among the histological subtypes. A linear strong correlation was demonstrated between BrdU LI and MIB-1 score (r = 0.732). Significant correlation was also found between BrdU LI and PCNA LR (r = 0.446); however, the relation between MIB-1 score and PCNA LR was weak. BrdU LI and MIB-1 score correlated positively with tumor size, TNM stage and overexpression of p53, and negatively with the presence of ER. PCNA LR correlated only with p53. These results indicate that MIB-1 is closely associated with BrdU in clinicopathologic findings and is a more useful tool for evaluating cell proliferation than PCNA. However, it will be necessary to consider the clinical significance of MIB-1 immunohistochemistry cautiously until further widespread clinical and pathological studies are performed.
采用溴脱氧尿苷（BrdU）、增殖标志物（MIB-1）和增殖细胞核抗原（PCNA）评估30例未经治疗的浸润性导管癌的增殖活性，并研究这些增殖标志物与组织学亚型和组织学分级之间的关系。此外，还检测了这些增殖标志物与p53蛋白过表达、c-erbB-2癌蛋白、雌激素受体（ER）状态及临床病理结果的相关性。BrdU标记指数（LI）、MIB-1评分和PCNA标记率（LR）与组织学分级相关。然而，各组织学亚型之间的增殖活性无统计学差异。BrdU LI与MIB-1评分之间呈线性强相关（r = 0.732）。BrdU LI与PCNA LR之间也存在显著相关性（r = 0.446）；然而，MIB-1评分与PCNA LR之间的关系较弱。BrdU LI和MIB-1评分与肿瘤大小、TNM分期及p53过表达呈正相关，与ER的存在呈负相关。PCNA LR仅与p53相关。这些结果表明，在临床病理结果方面，MIB-1与BrdU密切相关，并且在评估细胞增殖方面比PCNA更有用。然而，在进行进一步广泛的临床和病理研究之前，有必要谨慎考虑MIB-1免疫组化的临床意义。
